clinical trial · NCT05533697
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.·phase2·recruiting·n = 361
Advanced Solid TumorsmRNA-4359PembrolizumabIpilimumabNivolumab
brief summary
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
started
Sep 1, 2022
primary completion
Feb 18, 2032
completion
Feb 18, 2032
last updated
Apr 3, 2026
official title
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol